Company Overview
| Stock Name | Boan Biotech |
|---|---|
| Stock Code | 06955 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 一家綜合性生物製藥公司,致力於在中國及海外開發、製造及商業化不同治療領域的優質生物製品,專注於腫瘤、代謝、自身免疫及眼科等治療領域的生物類似藥及創新抗體藥物。 |
| Listing Date | 2022-12-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 山東省煙台市高新技術產業開發區科技大道39號 |
| Business Address (Hong Kong) | 香港九龍觀塘道348號宏利廣場5樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | boan-bio.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 19.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 3,960 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2022-12-19 to 2022-12-22 |
| Global Offering Shares | 10,694,800 shares |
| HK Public Offer Shares (Initial) | 1,069,600 shares (10.0%) |
| Public Offer Lots (Initial) | 5,348lots (Pool A2,674lots,Pool B2,674lots) |
| International Placing Shares (Initial) | 9,625,200 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 71.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 211,757,040 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,960 |
| 2 lots | 400 | HK$ 7,920 |
| 3 lots | 600 | HK$ 11,880 |
| 4 lots | 800 | HK$ 15,840 |
| 5 lots | 1,000 | HK$ 19,800 |
| 6 lots | 1,200 | HK$ 23,760 |
| 7 lots | 1,400 | HK$ 27,720 |
| 8 lots | 1,600 | HK$ 31,680 |
| 9 lots | 1,800 | HK$ 35,640 |
| 10 lots | 2,000 | HK$ 39,600 |
| 15 lots | 3,000 | HK$ 59,400 |
| 20 lots | 4,000 | HK$ 79,200 |
| 25 lots | 5,000 | HK$ 99,000 |
| 30 lots | 6,000 | HK$ 118,800 |
| 35 lots | 7,000 | HK$ 138,600 |
| 40 lots | 8,000 | HK$ 158,400 |
| 45 lots | 9,000 | HK$ 178,200 |
| 50 lots | 10,000 | HK$ 198,000 |
| 100 lots | 20,000 | HK$ 396,000 |
| 150 lots | 30,000 | HK$ 594,000 |
| 200 lots | 40,000 | HK$ 792,000 |
| 250 lots | 50,000 | HK$ 990,000 |
| 400 lots | 80,000 | HK$ 1,584,000 |
| 924 lots | 184,950 | HK$ 3,662,010 |
| 1,250 lots | 250,000 | HK$ 4,950,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,500 lots | 300,000 | HK$ 5,940,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 3.19B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +205% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣225.4百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2020 | 2021 |
|---|---|---|
| Revenue | 0 | 158,704 |
| Cost of sales | 0 | -52,190 |
| Gross profit | 0 | 106,514 |
| Other income and gains, net | 12,073 | 13,365 |
| Selling and distribution expenses | 0 | -54,048 |
| Administrative expenses | -4,464 | -42,165 |
| Net finance costs | -11,819 | -11,599 |
| Profit before tax | -240,538 | -225,417 |
| Income tax expense | 0 | 0 |
| Profit for the year | -240,538 | -225,417 |
| Profit attributable to owners | -240,538 | -225,417 |
Balance Sheet
| Item | 2020 | 2021 | 2022-06 |
|---|---|---|---|
| Cash and cash equivalents | 3,629 | 531,703 | |
| Trade and bills receivables | 700 | 107,267 | |
| Inventories | 19,672 | 98,840 | |
| Total current assets | 92,062 | 939,850 | |
| Total assets | 908,030 | 2,106,604 | |
| Total current liabilities | 396,177 | 260,482 | |
| Total liabilities | 426,441 | 554,917 | |
| Total equity | 481,589 | 1,551,687 | |
| Equity attributable to owners | 481,589 | 1,551,687 | |
| Interest-bearing borrowings | 0 | 250,000 | 251,680 |
Cash Flow Statement
| Item | 2020 | 2021 | 2022-06 |
|---|---|---|---|
| Net cash from operating activities | -506,720 | -246,278 | |
| Net cash from investing activities | -18,787 | -432,296 | |
| Depreciation of PP&E | 10,480 | 30,895 | 23,260 |
| Depreciation of right-of-use assets | 2,779 | 8,080 | 4,667 |
| Amortisation of intangible assets | 2,623 | 11,034 | 8,181 |
| Purchase of PP&E | -25,053 | -107,729 | -39,116 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 19.8 |
|---|---|
| First Day Open | HK$ 19.9 |
| First Day Change | -69.80% |
| First Day Volume | 1934930.0 |
| First Day Turnover | 38589400.0 |
| Use of Proceeds | 1、約59.5%或91.0百萬港元將用于核心產品的研發;
2、約31.4%或48.0百萬港元將用于我們管線中其他產品的研發;
3、約6.1%或9.3百萬港元將用于商業化目的;
4、約3.0%或4.6百萬港元將用于營運資金及其他一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (2)
Joint Bookrunners (2)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 99,997,920 HKD | — | 47.22% | — | 6 months | 2023-06-30 |
| 2 | 傅和亮 | 23,118,480 HKD | — | 10.92% | — | 6 months | 2023-06-30 |
| 3 | 中国生物制药有限公司 | 27,244,800 HKD | — | 12.87% | — | 6 months | 2023-06-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 姜華 | — |
| Company Secretary | 黎少娟 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 山東綠葉制藥有限公司(70.81%) |
|---|




